A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

Dry Eye Clinical Trial

— RESTA  

Official title:

A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03368404
• Other study ID #: 2017-A01099-44
• Status: Completed
• Phase: N/A
• Start date: November 9, 2017
• Est. completion date: March 9, 2021

Study information

• Verified date: October 2021
• Source: Laboratoire Chauvin
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, randomized, parallel group, investigator-masked, non-inferiority study. Approximately 84 subjects will be randomized in a 1:1 ratio.The primary objectives of this investigation are to show that the performance of CBL-102 Eye Drops is non-inferior to that of Vismed® Multi eye drops in subjects with moderate to severe keratoconjunctivitis sicca after 28 days, and to assess the safety of CBL-102 Eye Drops during a 90-day period with treatment administered 3 to 6 times per day. The primary performance endpoint for this study is the mean change from baseline (CFB) in the study eye at Visit 4 (Day 28 ± 3 days) in ocular surface fluorescein staining score.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 92
• Est. completion date: March 9, 2021
• Est. primary completion date: June 2, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects of legal age (at least 18) and able to read, understand, and provide written voluntary informed consent on the Ethics Committee (EC) approved Informed Consent Form

2. Subjects able and willing to comply with all treatment and follow-up and study procedures

3. Subjects who have been using tear substitutes for at least 2.5 months prior to inclusion, and who will use multidose preservative-free ART (Aqualarm® U.P. povidone 2% eye drops in 10 mL bottles) up to 6 times a day for at least 2 weeks immediately prior to randomization

4. Subjects with a score = 1 for at least 2 out of the 7 following symptoms (rated 0 to 4): sensation of dryness, foreign body, burning, stinging, itching, blurred vision, sensitivity to light

5. Subjects with at least 1 eye with the following signs of keratoconjunctivitis sicca :

• "Tear break-up time of 10 sec (mean of 3 measurements) at both screening visit and inclusion visit"
• "Total ocular surface staining score = 4 and = 9 at both screening visit and inclusion visit. This assessment combines corneal, nasal and temporal bulbar conjunctival fluorescein staining, each graded 0-5 according to the Oxford Scheme"

6. Subjects who have a decimal visual acuity (VA) with habitual correction equal to or better than 0.1 (Monoyer chart) in both eyes

7. Subjects with no systemic treatment or who are receiving stable systemic treatment (unchanged for 1 month or longer)

8. For Female subjects, they must fall into 1 of the following categories:

• "Post-menopausal"
• "Surgically sterile"
• "Using birth control method throughout the duration of the study"

9. For Female subjects who are of childbearing potential (i.e. who are not post-menopausal or not surgically sterile), they must have a negative urine pregnancy test result at screening

Exclusion Criteria:

1. Subjects with severe blepharitis

2. Subjects who have severe ocular dryness accompanied by 1 of the following:

• "Lid abnormality (except mild or moderate blepharitis)"
• "Corneal disease"
• "Ocular surface metaplasia"
• "Filamentary keratitis"
• "Corneal neovascularization"

3. Subjects who currently wear contact lenses or have worn contact lenses within 90 days prior to study start

4. Subjects who have received ocular surgery, including laser surgery, in either eye within 180 days prior to study start

5. Subjects with a history of ocular trauma, non-dry eye ocular inflammation, or ocular infection within 90 days prior to study start

6. Subjects with a history of ocular allergic disease or ocular herpes within 1 year prior to study start

7. Subjects with a history of any inflammatory ulcerative keratitis, recurrent corneal erosion, or uveitis

8. Subjects with known hypersensitivity or contraindications to any of the ingredients in the test or comparator products or ART

9. Subjects with initiation of, or changes to, concomitant medication that could affect dry eye within 30 days prior to Visit 1 (Screening) or with planned initiation or changes of such medications during the study

10. Subjects who have received ocular therapy (either eye) with any ophthalmic medication, except tear substitutes, within 2 weeks prior to study start

11. Subjects expected to receive ocular therapy during the study

12. Subjects treated with topical ocular steroidal or non-steroidal anti-inflammatory medication within 30 days prior to study start

13. Subjects expected to receive ocular therapy with immunosuppressants (eg, cyclosporine) during the study or who have used ocular immunosuppressants within 90 days prior to study start

14. Subjects who have received occlusion therapy with non resorbable lacrimal or punctum plugs within 90 days prior to study start or subjects with resorbable plugs

15. Subjects who have received or who are planned to receive therapy such as LipiFlow® or BlephEx®

16. Females who are breastfeeding

17. Subjects participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation

Related Conditions & MeSH terms

• Dry Eye
• Dry Eye Syndromes
• Keratoconjunctivitis Sicca

Intervention

Device:
• CBL-102 eye drops
CBL-102 eye drops, 3 to 6 times per day for 3 months
• Vismed Multi eye drops
Vismed Multi eye drops, 3 to 6 times per day for 3 months

Locations

Country	Name	City	State
France	Hôpital Kremlin-Bicêtre	Le Kremlin-Bicêtre

Sponsors (1)

Lead Sponsor	Collaborator
Laboratoire Chauvin

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse events questionnaire	Occurrence rates of ocular and non-ocular treatment emergent adverse events (TEAEs)	through study completion, an average of 3 months
Other	Visual acuity measurement	Visual acuity measurement using Monoyer scale	Baseline (Day 0), Visit 4 (Day 28) and Visit 5 (Day 90)
Primary	Total ocular surface fluorescein staining score at Visit 4	The primary performance endpoint for this study is the mean change from baseline (CFB) in the study eye in ocular surface fluorescein staining score according to a scale from 0 to 15, combining corneal, nasal and temporal bulbar conjunctival fluorescein staining, each graded 0 to 5, according to the Oxford Scheme	Baseline (Day 0), Visit 4 (Day 28)
Secondary	Total ocular fluorescein staining score at Visit 5	Mean CFB in the study eye in total ocular surface fluorescein staining score	Baseline (Day 0), Visit 5 (Day 90)
Secondary	Fluorescein staining score per area	Mean CFB in the study eye in fluorescein staining score for each area (cornea, nasal conjunctiva and temporal conjunctiva)	Baseline (Day 0), Visit 4 (Day 28) and Visit 5 (Day 90)
Secondary	TFBUT	Mean CFB in the study eye in tear film break-up time (TFBUT)	Baseline (Day 0), Visit 4 (Day 28) and Visit 5 (Day 90)
Secondary	Quality of Life questionnaire	Evolution from baseline of Ocular Surface Disease-Quality of Life (OSD-QoL®) questionnaire scores	Baseline (Day 0), Visit 5 (Day 90)
Secondary	Dry eye symptoms	Mean CFB in the global sum score of dry eye symptoms: sensation of dryness, foreign body, burning, stinging, itching, blurred vision, sensitivity to light, each graded from 0 to 4	Baseline (Day 0), Visit 4 (Day 28) and Visit 5 (Day 90)
Secondary	Schirmer test	Mean CFB in the study eye in volume of tear fluid secretion as assessed by the unanaesthetized Schirmer test	Baseline (Day 0), Visit 4 (Day 28)
Secondary	Questionnaire of daily frequency of instillations	Daily frequency of investigational eye drop instillations as reported in subject diary	through study completion, an average of 3 months